Clinical usefulness of prognostic biomarkers in optic neuritis
Background and purpose Different biological and radiological biomarkers predict clinical conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS). The aim was to explore their role in predicting the outcome of patients with optic neuritis (ON), a CIS considered to have a beni...
Gespeichert in:
| Veröffentlicht in: | European journal of neurology 2018-04, Vol.25 (4), p.614-618 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 618 |
|---|---|
| container_issue | 4 |
| container_start_page | 614 |
| container_title | European journal of neurology |
| container_volume | 25 |
| creator | Tejeda‐Velarde, A. Costa‐Frossard, L. Sainz de la Maza, S. Carrasco, Á. Espiño, M. Picón, C. Toboso, I. Walo, P. E. Lourido, D. Muriel, A. Álvarez‐Cermeño, J. C. Villar, L. M. |
| description | Background and purpose
Different biological and radiological biomarkers predict clinical conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS). The aim was to explore their role in predicting the outcome of patients with optic neuritis (ON), a CIS considered to have a benign prognosis.
Methods
Sixty‐eight consecutive ON patients were followed prospectively. Magnetic resonance imaging (MRI) and cerebrospinal fluid studies including oligoclonal immunoglobulin G (IgG) bands (OCGBs), lipid‐specific oligoclonal IgM bands (LS‐OCMBs) and neurofilament light chain quantification were performed at disease onset. Conversion to clinically definite MS (CDMS) was monitored.
Results
The mean time of follow‐up of our series was 46.4 months. Twenty‐five patients (36.7%) developed CDMS during follow‐up. Neurofilament light chain levels did not predict clinical conversion. By contrast, an abnormal MRI increased the risk of CDMS [hazard ratio (HR) 12.5, P = 0.013]. The clearest association was found in patients with more than three T2 lesions. OCGBs also predicted the onset of CDMS (HR 21.3, P = 0.003) and LS‐OCMBs were associated with a shorter time to CDMS (HR = 116.6, P |
| doi_str_mv | 10.1111/ene.13553 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1979968999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1979968999</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-40d01c90e8edd02fe6cdd37ddc631f25e5423d2dfb841d7f056b2a265e33c373</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMotlYX_gEZcKOLafNoMjMbQUp9QNFN92EmuZHUaVKTDtJ_b-pUF4J3cw-Xj8O5B6FLgsckzQQcjAnjnB2hIZmKMieMkeOkGSc5J5gM0FmMK4wxLSg-RQNa7QUvhuhu1lpnVd1mXQTTtQ5izLzJNsG_OR-3VmWN9es6vEOImXWZ3-xvDrpgtzaeoxNTtxEuDnuElg_z5ewpX7w-Ps_uF7linLF8ijUmqsJQgtaYGhBKa1ZorQQjhnLgU8o01aYpp0QXBnPR0JoKDowpVrARuultU6yPDuJWrm1U0La1A99FSaqiqkRZVVVCr_-gK98Fl8JJikkhSsEZSdRtT6ngYwxg5CbY9OVOEiz3ncrUqfzuNLFXB8euWYP-JX9KTMCkBz5tC7v_neT8Zd5bfgEv6X99</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2017686531</pqid></control><display><type>article</type><title>Clinical usefulness of prognostic biomarkers in optic neuritis</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Tejeda‐Velarde, A. ; Costa‐Frossard, L. ; Sainz de la Maza, S. ; Carrasco, Á. ; Espiño, M. ; Picón, C. ; Toboso, I. ; Walo, P. E. ; Lourido, D. ; Muriel, A. ; Álvarez‐Cermeño, J. C. ; Villar, L. M.</creator><creatorcontrib>Tejeda‐Velarde, A. ; Costa‐Frossard, L. ; Sainz de la Maza, S. ; Carrasco, Á. ; Espiño, M. ; Picón, C. ; Toboso, I. ; Walo, P. E. ; Lourido, D. ; Muriel, A. ; Álvarez‐Cermeño, J. C. ; Villar, L. M.</creatorcontrib><description>Background and purpose
Different biological and radiological biomarkers predict clinical conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS). The aim was to explore their role in predicting the outcome of patients with optic neuritis (ON), a CIS considered to have a benign prognosis.
Methods
Sixty‐eight consecutive ON patients were followed prospectively. Magnetic resonance imaging (MRI) and cerebrospinal fluid studies including oligoclonal immunoglobulin G (IgG) bands (OCGBs), lipid‐specific oligoclonal IgM bands (LS‐OCMBs) and neurofilament light chain quantification were performed at disease onset. Conversion to clinically definite MS (CDMS) was monitored.
Results
The mean time of follow‐up of our series was 46.4 months. Twenty‐five patients (36.7%) developed CDMS during follow‐up. Neurofilament light chain levels did not predict clinical conversion. By contrast, an abnormal MRI increased the risk of CDMS [hazard ratio (HR) 12.5, P = 0.013]. The clearest association was found in patients with more than three T2 lesions. OCGBs also predicted the onset of CDMS (HR 21.3, P = 0.003) and LS‐OCMBs were associated with a shorter time to CDMS (HR = 116.6, P < 0.001).
Conclusions
Magnetic resonance imaging and OCGBs predicted conversion to CDMS after an ON episode. In addition, LS‐OCMBs identified the ON patients more likely to develop MS early. These results, applicable to the everyday clinical setting, may be of interest for therapeutic decisions.
Click here for the corresponding questions to this CME article.</description><identifier>ISSN: 1351-5101</identifier><identifier>EISSN: 1468-1331</identifier><identifier>DOI: 10.1111/ene.13553</identifier><identifier>PMID: 29272057</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adult ; antibodies ; Biomarkers ; Cerebrospinal fluid ; Chains ; Cohort Studies ; Conversion ; demyelinating diseases ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin G ; Immunoglobulin G - cerebrospinal fluid ; Immunoglobulin M ; Immunoglobulin M - cerebrospinal fluid ; Lesions ; Light levels ; Magnetic Resonance Imaging ; Male ; Multiple sclerosis ; Multiple Sclerosis - cerebrospinal fluid ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - diagnostic imaging ; Neuritis ; Neurofilament Proteins - cerebrospinal fluid ; NMR ; Nuclear magnetic resonance ; Oligoclonal Bands ; Optic neuritis ; Optic Neuritis - cerebrospinal fluid ; Optic Neuritis - diagnosis ; Optic Neuritis - diagnostic imaging ; Patients ; Predictive Value of Tests ; Prognosis ; Prospective Studies ; Resonance ; Risk Assessment ; Treatment Outcome</subject><ispartof>European journal of neurology, 2018-04, Vol.25 (4), p.614-618</ispartof><rights>2017 EAN</rights><rights>2017 EAN.</rights><rights>Copyright © 2018 European Academy of Neurology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-40d01c90e8edd02fe6cdd37ddc631f25e5423d2dfb841d7f056b2a265e33c373</citedby><cites>FETCH-LOGICAL-c3533-40d01c90e8edd02fe6cdd37ddc631f25e5423d2dfb841d7f056b2a265e33c373</cites><orcidid>0000-0002-9067-3668 ; 0000-0002-7061-8725</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fene.13553$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fene.13553$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29272057$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tejeda‐Velarde, A.</creatorcontrib><creatorcontrib>Costa‐Frossard, L.</creatorcontrib><creatorcontrib>Sainz de la Maza, S.</creatorcontrib><creatorcontrib>Carrasco, Á.</creatorcontrib><creatorcontrib>Espiño, M.</creatorcontrib><creatorcontrib>Picón, C.</creatorcontrib><creatorcontrib>Toboso, I.</creatorcontrib><creatorcontrib>Walo, P. E.</creatorcontrib><creatorcontrib>Lourido, D.</creatorcontrib><creatorcontrib>Muriel, A.</creatorcontrib><creatorcontrib>Álvarez‐Cermeño, J. C.</creatorcontrib><creatorcontrib>Villar, L. M.</creatorcontrib><title>Clinical usefulness of prognostic biomarkers in optic neuritis</title><title>European journal of neurology</title><addtitle>Eur J Neurol</addtitle><description>Background and purpose
Different biological and radiological biomarkers predict clinical conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS). The aim was to explore their role in predicting the outcome of patients with optic neuritis (ON), a CIS considered to have a benign prognosis.
Methods
Sixty‐eight consecutive ON patients were followed prospectively. Magnetic resonance imaging (MRI) and cerebrospinal fluid studies including oligoclonal immunoglobulin G (IgG) bands (OCGBs), lipid‐specific oligoclonal IgM bands (LS‐OCMBs) and neurofilament light chain quantification were performed at disease onset. Conversion to clinically definite MS (CDMS) was monitored.
Results
The mean time of follow‐up of our series was 46.4 months. Twenty‐five patients (36.7%) developed CDMS during follow‐up. Neurofilament light chain levels did not predict clinical conversion. By contrast, an abnormal MRI increased the risk of CDMS [hazard ratio (HR) 12.5, P = 0.013]. The clearest association was found in patients with more than three T2 lesions. OCGBs also predicted the onset of CDMS (HR 21.3, P = 0.003) and LS‐OCMBs were associated with a shorter time to CDMS (HR = 116.6, P < 0.001).
Conclusions
Magnetic resonance imaging and OCGBs predicted conversion to CDMS after an ON episode. In addition, LS‐OCMBs identified the ON patients more likely to develop MS early. These results, applicable to the everyday clinical setting, may be of interest for therapeutic decisions.
Click here for the corresponding questions to this CME article.</description><subject>Adult</subject><subject>antibodies</subject><subject>Biomarkers</subject><subject>Cerebrospinal fluid</subject><subject>Chains</subject><subject>Cohort Studies</subject><subject>Conversion</subject><subject>demyelinating diseases</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - cerebrospinal fluid</subject><subject>Immunoglobulin M</subject><subject>Immunoglobulin M - cerebrospinal fluid</subject><subject>Lesions</subject><subject>Light levels</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - cerebrospinal fluid</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - diagnostic imaging</subject><subject>Neuritis</subject><subject>Neurofilament Proteins - cerebrospinal fluid</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Oligoclonal Bands</subject><subject>Optic neuritis</subject><subject>Optic Neuritis - cerebrospinal fluid</subject><subject>Optic Neuritis - diagnosis</subject><subject>Optic Neuritis - diagnostic imaging</subject><subject>Patients</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Resonance</subject><subject>Risk Assessment</subject><subject>Treatment Outcome</subject><issn>1351-5101</issn><issn>1468-1331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtLAzEUhYMotlYX_gEZcKOLafNoMjMbQUp9QNFN92EmuZHUaVKTDtJ_b-pUF4J3cw-Xj8O5B6FLgsckzQQcjAnjnB2hIZmKMieMkeOkGSc5J5gM0FmMK4wxLSg-RQNa7QUvhuhu1lpnVd1mXQTTtQ5izLzJNsG_OR-3VmWN9es6vEOImXWZ3-xvDrpgtzaeoxNTtxEuDnuElg_z5ewpX7w-Ps_uF7linLF8ijUmqsJQgtaYGhBKa1ZorQQjhnLgU8o01aYpp0QXBnPR0JoKDowpVrARuultU6yPDuJWrm1U0La1A99FSaqiqkRZVVVCr_-gK98Fl8JJikkhSsEZSdRtT6ngYwxg5CbY9OVOEiz3ncrUqfzuNLFXB8euWYP-JX9KTMCkBz5tC7v_neT8Zd5bfgEv6X99</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Tejeda‐Velarde, A.</creator><creator>Costa‐Frossard, L.</creator><creator>Sainz de la Maza, S.</creator><creator>Carrasco, Á.</creator><creator>Espiño, M.</creator><creator>Picón, C.</creator><creator>Toboso, I.</creator><creator>Walo, P. E.</creator><creator>Lourido, D.</creator><creator>Muriel, A.</creator><creator>Álvarez‐Cermeño, J. C.</creator><creator>Villar, L. M.</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9067-3668</orcidid><orcidid>https://orcid.org/0000-0002-7061-8725</orcidid></search><sort><creationdate>201804</creationdate><title>Clinical usefulness of prognostic biomarkers in optic neuritis</title><author>Tejeda‐Velarde, A. ; Costa‐Frossard, L. ; Sainz de la Maza, S. ; Carrasco, Á. ; Espiño, M. ; Picón, C. ; Toboso, I. ; Walo, P. E. ; Lourido, D. ; Muriel, A. ; Álvarez‐Cermeño, J. C. ; Villar, L. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-40d01c90e8edd02fe6cdd37ddc631f25e5423d2dfb841d7f056b2a265e33c373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>antibodies</topic><topic>Biomarkers</topic><topic>Cerebrospinal fluid</topic><topic>Chains</topic><topic>Cohort Studies</topic><topic>Conversion</topic><topic>demyelinating diseases</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - cerebrospinal fluid</topic><topic>Immunoglobulin M</topic><topic>Immunoglobulin M - cerebrospinal fluid</topic><topic>Lesions</topic><topic>Light levels</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - cerebrospinal fluid</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - diagnostic imaging</topic><topic>Neuritis</topic><topic>Neurofilament Proteins - cerebrospinal fluid</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Oligoclonal Bands</topic><topic>Optic neuritis</topic><topic>Optic Neuritis - cerebrospinal fluid</topic><topic>Optic Neuritis - diagnosis</topic><topic>Optic Neuritis - diagnostic imaging</topic><topic>Patients</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Resonance</topic><topic>Risk Assessment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tejeda‐Velarde, A.</creatorcontrib><creatorcontrib>Costa‐Frossard, L.</creatorcontrib><creatorcontrib>Sainz de la Maza, S.</creatorcontrib><creatorcontrib>Carrasco, Á.</creatorcontrib><creatorcontrib>Espiño, M.</creatorcontrib><creatorcontrib>Picón, C.</creatorcontrib><creatorcontrib>Toboso, I.</creatorcontrib><creatorcontrib>Walo, P. E.</creatorcontrib><creatorcontrib>Lourido, D.</creatorcontrib><creatorcontrib>Muriel, A.</creatorcontrib><creatorcontrib>Álvarez‐Cermeño, J. C.</creatorcontrib><creatorcontrib>Villar, L. M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tejeda‐Velarde, A.</au><au>Costa‐Frossard, L.</au><au>Sainz de la Maza, S.</au><au>Carrasco, Á.</au><au>Espiño, M.</au><au>Picón, C.</au><au>Toboso, I.</au><au>Walo, P. E.</au><au>Lourido, D.</au><au>Muriel, A.</au><au>Álvarez‐Cermeño, J. C.</au><au>Villar, L. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical usefulness of prognostic biomarkers in optic neuritis</atitle><jtitle>European journal of neurology</jtitle><addtitle>Eur J Neurol</addtitle><date>2018-04</date><risdate>2018</risdate><volume>25</volume><issue>4</issue><spage>614</spage><epage>618</epage><pages>614-618</pages><issn>1351-5101</issn><eissn>1468-1331</eissn><abstract>Background and purpose
Different biological and radiological biomarkers predict clinical conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS). The aim was to explore their role in predicting the outcome of patients with optic neuritis (ON), a CIS considered to have a benign prognosis.
Methods
Sixty‐eight consecutive ON patients were followed prospectively. Magnetic resonance imaging (MRI) and cerebrospinal fluid studies including oligoclonal immunoglobulin G (IgG) bands (OCGBs), lipid‐specific oligoclonal IgM bands (LS‐OCMBs) and neurofilament light chain quantification were performed at disease onset. Conversion to clinically definite MS (CDMS) was monitored.
Results
The mean time of follow‐up of our series was 46.4 months. Twenty‐five patients (36.7%) developed CDMS during follow‐up. Neurofilament light chain levels did not predict clinical conversion. By contrast, an abnormal MRI increased the risk of CDMS [hazard ratio (HR) 12.5, P = 0.013]. The clearest association was found in patients with more than three T2 lesions. OCGBs also predicted the onset of CDMS (HR 21.3, P = 0.003) and LS‐OCMBs were associated with a shorter time to CDMS (HR = 116.6, P < 0.001).
Conclusions
Magnetic resonance imaging and OCGBs predicted conversion to CDMS after an ON episode. In addition, LS‐OCMBs identified the ON patients more likely to develop MS early. These results, applicable to the everyday clinical setting, may be of interest for therapeutic decisions.
Click here for the corresponding questions to this CME article.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>29272057</pmid><doi>10.1111/ene.13553</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-9067-3668</orcidid><orcidid>https://orcid.org/0000-0002-7061-8725</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-5101 |
| ispartof | European journal of neurology, 2018-04, Vol.25 (4), p.614-618 |
| issn | 1351-5101 1468-1331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1979968999 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult antibodies Biomarkers Cerebrospinal fluid Chains Cohort Studies Conversion demyelinating diseases Disease Progression Female Follow-Up Studies Humans Immunoglobulin G Immunoglobulin G - cerebrospinal fluid Immunoglobulin M Immunoglobulin M - cerebrospinal fluid Lesions Light levels Magnetic Resonance Imaging Male Multiple sclerosis Multiple Sclerosis - cerebrospinal fluid Multiple Sclerosis - diagnosis Multiple Sclerosis - diagnostic imaging Neuritis Neurofilament Proteins - cerebrospinal fluid NMR Nuclear magnetic resonance Oligoclonal Bands Optic neuritis Optic Neuritis - cerebrospinal fluid Optic Neuritis - diagnosis Optic Neuritis - diagnostic imaging Patients Predictive Value of Tests Prognosis Prospective Studies Resonance Risk Assessment Treatment Outcome |
| title | Clinical usefulness of prognostic biomarkers in optic neuritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A29%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20usefulness%20of%20prognostic%20biomarkers%20in%20optic%20neuritis&rft.jtitle=European%20journal%20of%20neurology&rft.au=Tejeda%E2%80%90Velarde,%20A.&rft.date=2018-04&rft.volume=25&rft.issue=4&rft.spage=614&rft.epage=618&rft.pages=614-618&rft.issn=1351-5101&rft.eissn=1468-1331&rft_id=info:doi/10.1111/ene.13553&rft_dat=%3Cproquest_cross%3E1979968999%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2017686531&rft_id=info:pmid/29272057&rfr_iscdi=true |